US firm plans R&D centre in Bangalore

Hyderabad: The US-based Pikamab, a company engaged in drug development through monoclonal anti-bodies (MAB), plans to set up a research and development centre in Bangalore.

The proposed R&D centre is likely to hire around 50 scientists to work on efficacy of MABs in curing multiple cancers.

The company did not disclose the investment to be made in India.

Pikamab has been engaged in drug discovery research through monoclonal antibodies said Mr Vijay Ramakrishnan, Founder-Chief Executive Officer, Pikamab, California.

The monoclonal anti-bodies are administered to treat several solid tumours, haematological malignancies, inflammatory and auto-immune diseases.